Form Type: 4

SEC EDGAR Link
Accession Number:0001415889-22-005826
Date:2022-05-26
Issuer: SIGILON THERAPEUTICS, INC. (SGTX)
Original Submission Date:

Reporting Person:

COLE DOUGLAS G.
C/O SIGILON THERAPEUTICS, INC.
100 BINNEY STREET STE 600 CAMBRIDGE, MA 02142

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 0.7632 2022-05-26 deemed execution date A 8,888 (a) 2032-05-25 common stock 8,888 $0.76 8,888 direct
Footnotes
IDfootnote
f1 the option was issued pursuant to the sigilon therapeutics, inc. 2020 equity incentive plan. the option will vest as to 100% on may 26, 2023

Elevate your investments